AR044503A1 - Triazoles sustituidos con biarilo como bloqueantes del canal de sodio - Google Patents
Triazoles sustituidos con biarilo como bloqueantes del canal de sodioInfo
- Publication number
- AR044503A1 AR044503A1 ARP040100789A ARP040100789A AR044503A1 AR 044503 A1 AR044503 A1 AR 044503A1 AR P040100789 A ARP040100789 A AR P040100789A AR P040100789 A ARP040100789 A AR P040100789A AR 044503 A1 AR044503 A1 AR 044503A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- 4alkyl
- conrarb
- aryl
- ora
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de triazol substituidos con biarilo representados por la fórmula (1), (2) o (3) o sales farmacéuticamente aceptables de los mismos, y un proceso para preparar dichos compuestos y sales de los mismos. Las composiciones farmacéuticas comprenden una cantidad eficaz de los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos y un vehículo farmacéuticamente aceptable. Los procedimientos de tratamiento de afecciones asociadas a, o causadas por la actividad de canal de sodio, incluyendo por ejemplo, dolor agudo, dolor crónico, dolor visceral, dolor inflamatorio, dolor neuropático, epilepsia, síndrome del intestino irritable, depresión, ansiedad, esclerosis múltiple y trastorno bipolar, comprenden administrar una cantidad eficaz e los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos. Un procedimiento de administración de anestesia local, comprende administrar una cantidad eficaz de un compuesto de la presente, solo o en combinación con uno o más compuestos terapéuticamente activos, y un vehículo. Reivindicación 1: Un compuesto representado por la fórmula (1) o (2): o una sal farmacéuticamente aceptable del mismo, en la que R1 es (a) H; (b) alquilo C1-6, alquenilo C2-4, alquinilo C2-4,cicloalquilo C3-6, o alquil C1-4-[cicloalquilo C3-6], cualquiera de los cuales está opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-alquilo C1-4, O- CONRaRb , NRaRb, NRaCONRaRb, COO-alquilo C1-4, COOH, CN, CONRaRb, (c) -alquil C0-4-perfluoroalquilo C1-4; (d) NRaRb, N(CORa)Rb, -N(SO2Ra)Rb, -NRaCON(Ra)2, NRaSO2Ra, -N(ORa)CONRaRb, o -NRaSO2N(Ra)2; (e) -CH(ORa)Ra, -C(ORb)CF3, -CH(NHRb)Ra, -C(=O)Ra, C(=O)CF3, -SOCH3, -SO2CH3, COORa, CN, CONRaRb, -COCONRaRb, -SO2NRaRb, -CH2O-SO2NRaRb, SO2NRaORa, -C(=NH)NH2, -CRa=N-ORa, CH=CHCONRaRb; (f) -CONRa(CH2)0-2CRaRb(CH2)0-2CONRaRb; (g) -CRa=CRbCOORa, o -CRa=CRb-CONRaRb; Ra es (a) H; (b) alquilo, opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-alquilo C1-4, S(O)0-2-alquilo C1-4, -OCONH2, -OCONHalquilo C1-4, -OCONalquil C1-4alquilo C1-4, -OCONHalquil C1-4-arilo, -OCON(alquil C1-4)(alquil C1-4-aril), NH2, NHalquilo C1-4, N(alquil C1-4)(alquilo C1-4), NH(alquil C1-4-arilo), N(alquil C1-4)(alquil C1-4-arilo), NHCONH2, NHCONH(alquilo C1-4), NHCONH(alquil C1-4-arilo), -NHCON(alquil C1-4)(alquilo C1-4), NHCON(alquil C1-4)(alquil C1-4-arilo), N(alquil C1-4)CON(alquil C1-4)(alquilo C1-4), N(alquil C1-4)CON(alquil C1-4)(alquil C1-4-arilo), COO-(alquilo C1-4), COOH, CN, CONH2, CONH(alquilo C1-4), CON(alquil C1-4)(alquilo C1-4); (c) alquil C0-4-()perfluoroalquilo C1-4; o (d) -alquil C1-4-arilo, siendo el arilo fenilo, piridilo, pirimidinilo, furilo, tienilo, pirrolilo, triazolilo, pirazolilo, tiazolilo, isoxazolilo, oxazolilo, u oxadiazolilo, estando cualquier arilo opcionalmente substituido con 1-3 substituyentes seleccionados de i) F, Cl, Br, I, ii) -CN, iii) -NO2, iv) -C(-O)(alquilo C1-4), v) -O(alquilo C1-4) , vi) -N(alquil C1-4)(alquilo C1-4) , vii) -alquilo C1-10, y viii) -alquilo C1-10,pudiendo estar reemplazado uno o más de los carbonos alquílicos por un -O-, -S(O)1-2-, -O- C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, o -CºC-; Rb es (a) H; o (b) alquilo C1-6, opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-alquilo C1-4, S(O)0-2-()alquilo C1-4, -OCONH2, -OCONH(alquilo C1-4), NH2, NH(alquilo C1-4), N(alquil C1-4)(alquilo C1-4), NHCONH2, NHCONH(alquilo C1-4), -NHCON(alquil C1-4)(alquilo C1-4), COO-(alquilo C1-4), COOH, CN, o CONH2; R2 es: (a) H; (b) -alquilo C1-4, -cicloalquilo C3-6 o -alquil C1-4-()cicloalquilo C3-6, opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-alquilo C1-4, S(O)0-2-alquilo C1-4, O-CONRaRb , NRaRb , NRaCONRaRb , COO-alquilo C1-4, COOH, CN, CONRaRb; (c) -alquil C0-4-perfluoroalquilo C1-4; (d) -C(=O)Ra, - CONRaRb , -COO-alquilo C1-4, -SO2Ra , -SO2NRaRb; R3 y R4 es independientemente: (a) H; (b) -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6 o -cicloalquilo C3-6, estando cualquiera de ellos opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, -O-alquilo C1-4, CN, -NRaRb, -NRaCO-alquilo C1-4, COORb , CONRaRb o fenilo; (c) ) -alquil C0-4-perfluoroalquilo C1-4, o -O-alquil C0-4-perfluoroalquilo C1-4; (d) CN, NH2, NO2, F, Cl, Br, I, OH, OCONRaRb, O(-alquil C1- 4)CONRaRb , -OSO2NRaRb, COORb , CONRaRb, o arilo, estando el arilo opcionalmente substituido con 1-3 substituyentes seleccionados de i) F, Cl, Br, I, ii) -CN, iii) -NO2, iv) -C(=O)Ra, v) -ORa , vi) -NRaRb , vii) -C0-4alquil C0-4-CO-ORa , viii) -(C0- 4alquil C0-4)-NH-CO-ORa , ix) -(C0-4alquil C0-4)-CO-NRaRb, x) -S(O)0-2Ra , xi) -SO2NRaRb, xii) -NRaSO2Ra , xiii) -alquilo C1-10, y xiv) -alquilo C1-10,pudiendo estar reemplazado uno o más de los carbonos alquílicos por un -NRa -, -O-, -S(O)1-2-, -O- C(O)-, -C(O)-O-, -C(O)-NRa-, -NRa-C(O)-, -NRa-C(O)-NRa, -C(O)-, -CH(OH)-, -C=C-, o -CºC-; y cada R5 , R6 y R7 es independientemente: (a) H; (b) alquilo C1-6, alquenilo C2-4, alquinilo C2-4 o cicloalquilo C3-6, cualquiera de los cuales está opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-()alquilo C1-4, OCONRaRb, NRaRb, COORa , CN, CONRaRb , N(RaRb)CONRaRb ;(c) -O-alquilo C1-6, -O-cicloalquilo C3-6, -S-alquilo C1-6 o -S-cicloalquilo C3-6, cualquiera de los cuales está opcionalmente substituido con uno o más de los siguientes substituyentes: F, CF3, OH, O-alquilo C1-4, NH2, NH(alquilo C1-4), N(alquilo C1-4)2, COOH, CN, CONH2, CONH(alquilo C1-4), CONH(alquilo C1-4)2, SO2NH2, SO2NH(alquilo C1-4), tetrazolilo, triazolilo, imidazolilo, oxazolilo, oxadiazolilo, isooxazolilo, tiazolilo, furilo, tienilo, pirazolilo, pirrolilo, piridilo, pirimidinilo, pirazinilo, fenilo, piperidinilo, morfolinilo, pirrolidinilo, o piperazinilo; (d) -alquil C0-4-perfluoroalquilo C1-4, o -O-alquil C0-4-perfluoroalquilo C1-4; (e) CN, NRaRb, NO2, F, Cl, Br, I, -ORa , -SRa , -OCONRaRb, -OSO2NRaRb, COORb , CONRaRb, -NRaCONRaRb, -NRaSO2NRaRb, -C(ORb)Ra , -C(ORa)CF3, -C(NHRa)CF3, - C(=O)Ra, C(=O)CF3, -SOCH3, -SO2CH3, -NHSO2(C1-6alquilo C1-6), -NHSO2-arilo, SO2NRaRb, -CH2OSO2NRaRb, SO2NRb-ORa , -C(=NH)NH2, -CRa-N-ORa , CH=CH o arilo, estando el arilo opcionalmente substituido con 1-3 substituyentes seleccionados de i) F, Cl, Br, I, ii) -CN, iii) -NO2, iv) -C(=O)Ra, v) -ORa , vi) -NRaRb , vii) -C0-4alquil C0-4-CO-ORa , viii) -(C0-4alquil C0-4)-NH-CO-ORa , ix) -(C0-4alquil C0-4)-CO-NRaRb, x) -S(O)0-2Ra , xi) -SO2NRaRb, xii) -NRaSO2Ra , xiii) - alquilo C1-10, y xiv) - alquilo C1-10, pudiendo estar reemplazado uno o más de los carbonos alquílicos por un -NRa -, -O-, -S(O)1-2-, -O-C(O)-, -C(O)-O-, -C(O)-NRa-, -NRa-C(O)-, -NRa-C(O)-NRa, -C(O)-, -CH(OH)-, -C=C-, o -CºC-. Reivindicación 2: Un compuesto representado por la fórmula (3), o una sal farmacéuticamente aceptable del mismo, en la que cada R1-R7 es como se ha definido en la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45595203P | 2003-03-18 | 2003-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044503A1 true AR044503A1 (es) | 2005-09-14 |
Family
ID=33030073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100789A AR044503A1 (es) | 2003-03-18 | 2004-03-11 | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7326726B2 (es) |
| EP (1) | EP1606269B1 (es) |
| JP (1) | JP4482554B2 (es) |
| KR (1) | KR100737721B1 (es) |
| CN (2) | CN1788002A (es) |
| AR (1) | AR044503A1 (es) |
| AT (1) | ATE412639T1 (es) |
| AU (1) | AU2004221885C1 (es) |
| BR (1) | BRPI0408407A (es) |
| CA (1) | CA2519252C (es) |
| CL (1) | CL2004000551A1 (es) |
| CY (1) | CY1108720T1 (es) |
| DE (1) | DE602004017438D1 (es) |
| DK (1) | DK1606269T3 (es) |
| EC (1) | ECSP056018A (es) |
| EG (1) | EG25994A (es) |
| ES (1) | ES2314387T3 (es) |
| HR (1) | HRP20050816A2 (es) |
| IS (1) | IS8001A (es) |
| JO (1) | JO2480B1 (es) |
| MA (1) | MA27665A1 (es) |
| MX (1) | MXPA05009847A (es) |
| MY (1) | MY142651A (es) |
| NO (1) | NO20054775L (es) |
| NZ (1) | NZ542205A (es) |
| PE (1) | PE20041066A1 (es) |
| PL (1) | PL1606269T3 (es) |
| PT (1) | PT1606269E (es) |
| RU (1) | RU2356897C2 (es) |
| SI (1) | SI1606269T1 (es) |
| TW (1) | TWI337605B (es) |
| UA (1) | UA81660C2 (es) |
| WO (2) | WO2004083189A1 (es) |
| ZA (1) | ZA200506906B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101413143B (zh) | 2002-12-19 | 2013-09-18 | 斯克里普斯研究学院 | 稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法 |
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| RU2372339C2 (ru) * | 2003-11-10 | 2009-11-10 | Мерк Энд Ко., Инк. | Замещенные триазолы в качестве блокаторов натриевых каналов |
| AU2005245470A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| JP2010516734A (ja) * | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物 |
| NZ579403A (en) * | 2007-02-08 | 2012-03-30 | Synta Pharmaceuticals Corp | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
| EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
| ME02847B (me) | 2009-07-27 | 2018-01-20 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| WO2013038351A1 (en) | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
| WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| JP2020536870A (ja) | 2017-10-05 | 2020-12-17 | バイオジェン インコーポレイテッド | アルファカルボキサミドピロリジン誘導体の調製方法 |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| US20210002232A1 (en) * | 2018-03-09 | 2021-01-07 | Pi Industries Ltd. | Heterocyclic compounds as fungicides |
| CN108794413A (zh) * | 2018-06-25 | 2018-11-13 | 青岛科技大学 | 一种1,2,4-三氮唑-3-甲酰胺的合成方法 |
| CN108863965A (zh) * | 2018-06-25 | 2018-11-23 | 青岛科技大学 | 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US875782A (en) * | 1907-04-29 | 1908-01-07 | Walter H Cook | Fast-nut. |
| TW226993B (es) * | 1992-05-29 | 1994-07-21 | Kumiai Chemical Industry Co | |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| IT1292091B1 (it) * | 1997-06-05 | 1999-01-25 | Geange Ltd | Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| UA72244C2 (en) * | 1999-03-26 | 2005-02-15 | Aryl-substituted pyrazols, imidazols, oxazols, thiazols, pyrrols and their use | |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| CA2445568A1 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| US6797722B2 (en) * | 2002-05-03 | 2004-09-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases |
| MXPA05000279A (es) * | 2002-07-09 | 2005-03-31 | Squibb Bristol Myers Co | Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo. |
| KR100467668B1 (ko) * | 2002-08-07 | 2005-01-24 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| KR100470075B1 (ko) * | 2002-11-21 | 2005-02-05 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| RU2372339C2 (ru) * | 2003-11-10 | 2009-11-10 | Мерк Энд Ко., Инк. | Замещенные триазолы в качестве блокаторов натриевых каналов |
-
2004
- 2004-03-11 AR ARP040100789A patent/AR044503A1/es unknown
- 2004-03-11 MY MYPI20040842A patent/MY142651A/en unknown
- 2004-03-12 ES ES04720360T patent/ES2314387T3/es not_active Expired - Lifetime
- 2004-03-12 CN CNA200480013089XA patent/CN1788002A/zh active Pending
- 2004-03-12 WO PCT/US2004/007597 patent/WO2004083189A1/en not_active Ceased
- 2004-03-12 CA CA002519252A patent/CA2519252C/en not_active Expired - Fee Related
- 2004-03-12 AT AT04720360T patent/ATE412639T1/de active
- 2004-03-12 PT PT04720360T patent/PT1606269E/pt unknown
- 2004-03-12 BR BRPI0408407-1A patent/BRPI0408407A/pt not_active IP Right Cessation
- 2004-03-12 JP JP2006507122A patent/JP4482554B2/ja not_active Expired - Fee Related
- 2004-03-12 DE DE602004017438T patent/DE602004017438D1/de not_active Expired - Lifetime
- 2004-03-12 NZ NZ542205A patent/NZ542205A/en not_active IP Right Cessation
- 2004-03-12 US US10/799,230 patent/US7326726B2/en not_active Expired - Lifetime
- 2004-03-12 MX MXPA05009847A patent/MXPA05009847A/es active IP Right Grant
- 2004-03-12 CN CNA2008101000997A patent/CN101289428A/zh active Pending
- 2004-03-12 DK DK04720360T patent/DK1606269T3/da active
- 2004-03-12 RU RU2005132168/04A patent/RU2356897C2/ru not_active IP Right Cessation
- 2004-03-12 SI SI200430959T patent/SI1606269T1/sl unknown
- 2004-03-12 WO PCT/US2004/007830 patent/WO2004083190A1/en not_active Ceased
- 2004-03-12 KR KR1020057017327A patent/KR100737721B1/ko not_active Expired - Fee Related
- 2004-03-12 HR HR20050816A patent/HRP20050816A2/hr not_active Application Discontinuation
- 2004-03-12 EP EP04720360A patent/EP1606269B1/en not_active Expired - Lifetime
- 2004-03-12 UA UAA200509759A patent/UA81660C2/ru unknown
- 2004-03-12 PL PL04720360T patent/PL1606269T3/pl unknown
- 2004-03-12 AU AU2004221885A patent/AU2004221885C1/en not_active Ceased
- 2004-03-14 JO JO200430A patent/JO2480B1/en active
- 2004-03-16 PE PE2004000280A patent/PE20041066A1/es not_active Application Discontinuation
- 2004-03-17 TW TW093107083A patent/TWI337605B/zh not_active IP Right Cessation
- 2004-03-17 CL CL200400551A patent/CL2004000551A1/es unknown
-
2005
- 2005-08-29 IS IS8001A patent/IS8001A/is unknown
- 2005-08-29 ZA ZA200506906A patent/ZA200506906B/xx unknown
- 2005-09-06 MA MA28481A patent/MA27665A1/fr unknown
- 2005-09-14 EC EC2005006018A patent/ECSP056018A/es unknown
- 2005-09-18 EG EGNA2005000548 patent/EG25994A/xx active
- 2005-10-17 NO NO20054775A patent/NO20054775L/no not_active Application Discontinuation
-
2008
- 2008-01-30 US US12/011,967 patent/US7572822B2/en not_active Expired - Lifetime
-
2009
- 2009-01-15 CY CY20091100054T patent/CY1108720T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044503A1 (es) | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio | |
| RU2009114167A (ru) | Комбинации специфических ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом | |
| RU2495878C2 (ru) | Гетероциклические антивирусные соединения | |
| RU2008112683A (ru) | Ингибиторы fap | |
| RU2007121219A (ru) | Диазациклоалканы как агонисты окситоцина | |
| JP2013537907A5 (es) | ||
| RU2002135312A (ru) | Средство, усиливающие секрецию гормона роста | |
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| JP2013525318A5 (es) | ||
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| AR046061A1 (es) | Derivados de acilhidrazona | |
| RU2013116541A (ru) | Сложноэфирные пролекарства [3-(1-(1h-имидазол-4-ил)этил)-2-метилфенил]метанола | |
| JP2002536300A5 (es) | ||
| RU2011121354A (ru) | Синтетические миметики иммунной защиты и их применение | |
| AR029412A1 (es) | Forma cristalina | |
| RU2014132565A (ru) | Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующийм альфа-v-бета-3 | |
| JP2006524227A5 (es) | ||
| RU2002107453A (ru) | Пиразоло[4,3-d] пиримидины | |
| RU98113304A (ru) | Новые фосфолипидные производные фосфонокарбоновых кислот, их получение и применение в качестве антивирусных лекарственных средств | |
| JP2005523281A5 (es) | ||
| RU2015110006A (ru) | Замещенные соединения цианопиразола в качестве антагонистов лизофосфатидной кислоты | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| RU2008113187A (ru) | Лечение аутоиммунных заболеваний | |
| AR026704A1 (es) | Forma cristalina | |
| AR120859A1 (es) | Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |